TriSalus Life Sciences, Inc.
TLSI · XNASCIK 1826667fmd_0VAWQZ2JMC1M9T05SW2V7K73TZManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 02, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | 12 | 19 | 29 | 45 |
| Cost of revenue | – | 2 | 3 | 4 | 7 |
| Gross profit | – | 10 | 16 | 25 | 38 |
| Research and development | – | 21 | 30 | 18 | 15 |
| Selling, general and administrative | – | 25 | 41 | 44 | 50 |
| Operating income | (3) | (36) | (54) | (36) | (27) |
| Interest expense | – | 0 | 0 | 3 | 6 |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | 8 | (0) | (0) | (0) | (0) |
| Income before taxes | 5 | (47) | (59) | (30) | (39) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 5 | (47) | (59) | (30) | (39) |
| Net income | 5 | (47) | (59) | (30) | (39) |
| Net income to common shareholders | – | (50) | (64) | (33) | (70) |